Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 21 studies | 25% ± 7% | |
macrophage | 9 studies | 22% ± 5% | |
endothelial cell of lymphatic vessel | 7 studies | 23% ± 4% | |
ciliated cell | 7 studies | 22% ± 8% | |
fibroblast | 7 studies | 21% ± 4% | |
glutamatergic neuron | 6 studies | 38% ± 22% | |
epithelial cell | 6 studies | 41% ± 12% | |
retinal rod cell | 6 studies | 24% ± 3% | |
adipocyte | 6 studies | 22% ± 4% | |
astrocyte | 6 studies | 27% ± 9% | |
oligodendrocyte | 6 studies | 24% ± 7% | |
microglial cell | 5 studies | 23% ± 7% | |
basal cell | 5 studies | 25% ± 7% | |
lymphocyte | 5 studies | 22% ± 4% | |
goblet cell | 5 studies | 29% ± 12% | |
natural killer cell | 4 studies | 16% ± 1% | |
non-classical monocyte | 4 studies | 28% ± 11% | |
capillary endothelial cell | 4 studies | 17% ± 1% | |
neuron | 4 studies | 28% ± 9% | |
myeloid cell | 4 studies | 30% ± 7% | |
mast cell | 4 studies | 26% ± 9% | |
retinal cone cell | 4 studies | 31% ± 12% | |
type I pneumocyte | 4 studies | 20% ± 2% | |
GABAergic neuron | 4 studies | 43% ± 16% | |
oligodendrocyte precursor cell | 4 studies | 28% ± 9% | |
monocyte | 4 studies | 22% ± 3% | |
interneuron | 4 studies | 35% ± 19% | |
classical monocyte | 3 studies | 25% ± 7% | |
B cell | 3 studies | 20% ± 5% | |
glomerular endothelial cell | 3 studies | 17% ± 1% | |
retinal bipolar neuron | 3 studies | 25% ± 6% | |
squamous epithelial cell | 3 studies | 38% ± 27% | |
club cell | 3 studies | 25% ± 2% | |
rod bipolar cell | 3 studies | 22% ± 4% | |
respiratory goblet cell | 3 studies | 24% ± 6% | |
secretory cell | 3 studies | 19% ± 1% | |
type II pneumocyte | 3 studies | 23% ± 6% | |
dendritic cell | 3 studies | 25% ± 10% | |
abnormal cell | 3 studies | 22% ± 8% | |
enteroendocrine cell | 3 studies | 23% ± 3% | |
pericyte | 3 studies | 18% ± 3% | |
alveolar macrophage | 3 studies | 27% ± 7% | |
cardiac muscle cell | 3 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2520.75 | 1445 / 1445 | 100% | 33.44 | 183 / 183 |
lung | 100% | 3152.49 | 578 / 578 | 100% | 30.50 | 1155 / 1155 |
prostate | 100% | 2507.28 | 245 / 245 | 100% | 30.80 | 502 / 502 |
stomach | 100% | 1895.25 | 359 / 359 | 100% | 30.98 | 286 / 286 |
uterus | 100% | 2660.68 | 170 / 170 | 100% | 26.62 | 459 / 459 |
brain | 100% | 2879.00 | 2642 / 2642 | 100% | 30.81 | 704 / 705 |
thymus | 100% | 3161.01 | 653 / 653 | 100% | 35.09 | 604 / 605 |
intestine | 100% | 2748.18 | 966 / 966 | 100% | 29.91 | 526 / 527 |
breast | 100% | 2720.13 | 459 / 459 | 100% | 35.17 | 1115 / 1118 |
adrenal gland | 100% | 2721.02 | 258 / 258 | 100% | 21.79 | 229 / 230 |
ovary | 100% | 2419.18 | 180 / 180 | 100% | 16.85 | 428 / 430 |
bladder | 100% | 2490.90 | 21 / 21 | 99% | 27.86 | 501 / 504 |
kidney | 100% | 2455.82 | 89 / 89 | 99% | 23.63 | 895 / 901 |
pancreas | 100% | 1854.57 | 327 / 328 | 99% | 26.35 | 177 / 178 |
liver | 100% | 2201.34 | 226 / 226 | 95% | 15.84 | 387 / 406 |
skin | 100% | 2719.48 | 1808 / 1809 | 93% | 19.83 | 440 / 472 |
adipose | 100% | 2799.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2589.62 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.63 | 29 / 29 |
muscle | 100% | 2533.96 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2653.33 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 26.74 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.76 | 1 / 1 |
heart | 99% | 1712.27 | 855 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 86% | 1630.79 | 798 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 65% | 8.83 | 52 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0070427 | Biological process | nucleotide-binding oligomerization domain containing 1 signaling pathway |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0030510 | Biological process | regulation of BMP signaling pathway |
GO_0006974 | Biological process | DNA damage response |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0045088 | Biological process | regulation of innate immune response |
GO_0051402 | Biological process | neuron apoptotic process |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0042742 | Biological process | defense response to bacterium |
GO_0070424 | Biological process | regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway |
GO_0097340 | Biological process | inhibition of cysteine-type endopeptidase activity |
GO_0070431 | Biological process | nucleotide-binding oligomerization domain containing 2 signaling pathway |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_1902530 | Biological process | positive regulation of protein linear polyubiquitination |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0055070 | Biological process | copper ion homeostasis |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0060785 | Biological process | regulation of apoptosis involved in tissue homeostasis |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004869 | Molecular function | cysteine-type endopeptidase inhibitor activity |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0043027 | Molecular function | cysteine-type endopeptidase inhibitor activity involved in apoptotic process |
GO_0042802 | Molecular function | identical protein binding |
GO_0120283 | Molecular function | protein serine/threonine kinase binding |
GO_0061135 | Molecular function | endopeptidase regulator activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | XIAP |
Protein name | RING-type E3 ubiquitin transferase (EC 2.3.2.27) E3 ubiquitin-protein ligase XIAP (EC 2.3.2.27) (Baculoviral IAP repeat-containing protein 4) (IAP-like protein) (ILP) (hILP) (Inhibitor of apoptosis protein 3) (IAP-3) (hIAP-3) (hIAP3) (RING-type E3 ubiquitin transferase XIAP) (X-linked inhibitor of apoptosis protein) (X-linked IAP) E3 ubiquitin-protein ligase XIAP |
Synonyms | BIRC4 IAP3 API3 |
Description | FUNCTION: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis . Acts as a direct caspase inhibitor . Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry . Inactivates CASP9 by keeping it in a monomeric, inactive state . Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS, PTEN and BIRC5/survivin . Acts as an important regulator of innate immunity by mediating 'Lys-63'-linked polyubiquitination of RIPK2 downstream of NOD1 and NOD2, thereby transforming RIPK2 into a scaffolding protein for downstream effectors, ultimately leading to activation of the NF-kappa-B and MAP kinases signaling . 'Lys-63'-linked polyubiquitination of RIPK2 also promotes recruitment of the LUBAC complex to RIPK2 . Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation . Ubiquitination of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation . Ubiquitination of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation . Plays a role in copper homeostasis by ubiquitinating COMMD1 and promoting its proteasomal degradation . Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation . Ubiquitinates and therefore mediates the proteasomal degradation of BCL2 in response to apoptosis . Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner . Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8 . Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES . Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program . . |
Accessions | ENST00000355640.3 ENST00000371199.8 ENST00000430625.1 ENST00000422098.5 ENST00000422098.6 B1AKU2 P98170 B1AKU3 |